Joseph Haas

<p>Norgine will market Pedmark, indicated to reduce risk of chemotherapy-related hearing loss in pediatric cancer, in the EU and UK. It will seek additional approvals in Australia and New Zealand.</p>

<p>The $16.5bn deal, intended to increase Novo Nordisk’s production of semaglutide-containing products, led a $36bn-plus quarter for M&A transactions, according to Evaluate.</p>

<p>Roivant’s brepocitinib bests data Humira previously posted in non-infectious uveitis, a top cause of blindness. The TYK2/JAK1 inhibitor also is in Phase III for dermatomyositis.</p>

<p>Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.</p>

<p>The privately held biotech will bring J&J a pair of bispecific antibodies expected to target multiple pathologic pathways in atopic dermatitis and asthma.</p>

<p>An extension of the pivotal study backing Zepbound (tirzepatide)’s approval for obesity demonstrated 94% risk reduction for type 2 diabetes as well as sustained weight loss over three years.</p>

<p>Deal Snapshot: The Belgian company follows a tradition of Western pharma companies relying on local expertise to market their products in China.</p>

<p>In a multiple-ascending dose Phase I trial, Terns’ oral GLP-1 agonist showed 4.9% placebo-adjusted weight loss at 28 weeks, with no severe gastrointestinal side effects.</p>

<p>Phase III success positions Scholar Rock’s selective myostatin inhibitor for regulatory filings in early 2025. Analysts see a blockbuster opportunity for additive therapy in spinal muscular atrophy.</p>

<p>The biopharma industry posted 22 mergers and acquisitions during the third quarter, according to Evaluate, for a total of $8.2bn. Those tallies marked a second consecutive quarter of decline.</p>